Paclitaxel has shown remarkable efficacy in the treatment of cancer, but the emergence of drug resistant tumor cells limits its ability to cure disease. The long term goal of the studies described here is to define the molecular mechanisms of drug resistance. Destabilization of microtubule assembly by mutations in tubulin represents a major mechanism of resistance to paclitaxel. Preliminary studies indicate that these mutations alter 3 closely spaced leucine residues in beta-tubulin. To understand this mechanism at a detailed molecular level, the following questions will be addressed: 1) Do all paclitaxel resistance mutations map to the same area of beta-tubulin and do mutations in alpha-tubulin also cluster in one area of the gene? Tubulin genes from existing paclitaxel resistant CHO cells will be sequenced, and additional mutants will be created by transfecting wild-type cells with randomly mutagenized alpha- and beta-tubulin cDNAs. 2) Why are only a limited set of amino acid residues involved in conferring resistance to paclitaxel? Site-directed mutagenesis, transfection, and assays for tubulin assembly and paclitaxel resistance will be used to test the tolerance for small vs. large, hydrophobic vs. hydrophilic, and charged vs. uncharged substitutions at the 3 altered leucine and at other adjacent amino acid residues. 3) What is the topological and functional significance of this region? The 3 altered leucines primarily affect a loop connecting helices 6 and 7 of beta-tubulin. Second-site suppressor analysis and chemical crosslinking will be used to determine what interacts with this loop. Antibodies, fluorescent reporters, and inhibitory peptides will be used to determine whether the loop becomes buried when microtubules assemble and whether site-specific agents can inhibit assembly in vitro. 4) Can principles derived from studying one cell type be extrapolated to other cell types? The role of beta-tubulin isotopes in drug resistance will be studied using site-directed mutagenesis and transfection of different isotypes. Also, the frequencies of different resistance mechanisms will be tested in human cell lines surviving paclitaxel treatment. The studies in this proposal will elucidate the mechanism of action of paclitaxel and define a major mechanism by which cells can escape the cytotoxicity of the drug. This knowledge should lead to better paclitaxel analogs, to improved strategies for circumventing paclitaxel resistance, and to the development of diagnostic tests for the detection of paclitaxel resistant tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA085935-02
Application #
6377830
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
2000-04-01
Project End
2005-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
2
Fiscal Year
2001
Total Cost
$269,100
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Biology
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Ganguly, Anutosh; Yang, Hailing; Zhang, Hong et al. (2013) Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Mol Cancer Ther 12:2837-46
Yin, Shanghua; Zeng, Changqing; Hari, Malathi et al. (2013) Paclitaxel resistance by random mutagenesis of ?-tubulin. Cytoskeleton (Hoboken) 70:849-62
Ganguly, Anutosh; Yang, Hailing; Sharma, Ritu et al. (2012) The role of microtubules and their dynamics in cell migration. J Biol Chem 287:43359-69
Yin, Shanghua; Zeng, Changqing; Hari, Malathi et al. (2012) Random mutagenesis of ?-tubulin defines a set of dispersed mutations that confer paclitaxel resistance. Pharm Res 29:2994-3006
Ganguly, Anutosh; Bhattacharya, Rajat; Cabral, Fernando (2012) Control of MCAK degradation and removal from centromeres. Cytoskeleton (Hoboken) 69:303-11
Ganguly, Anutosh; Yang, Hailing; Cabral, Fernando (2011) Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol Cancer Ther 10:929-37
Ganguly, Anutosh; Yang, Hailing; Cabral, Fernando (2011) Class III ýý-tubulin counteracts the ability of paclitaxel to inhibit cell migration. Oncotarget 2:368-77
Ganguly, Anutosh; Yang, Hailing; Pedroza, Mesias et al. (2011) Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistance. J Biol Chem 286:36378-84
Ganguly, Anutosh; Cabral, Fernando (2011) New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta 1816:164-71
Yang, Hailing; Ganguly, Anutosh; Yin, Shanghua et al. (2011) Megakaryocyte lineage-specific class VI ýý-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. Cytoskeleton (Hoboken) 68:175-87

Showing the most recent 10 out of 28 publications